# 4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists
Canonical URL: https://biopharmsignal.com/news/FDMT/4dmt-announces-presentation-at-44th-annual-scientific-meeting-of-the-american-so-2d1eff08
Ticker: FDMT
Company: 4D Molecular Therapeutics, Inc.
Source: 4D Molecular Therapeutics, Inc.
Published: 2026-06-30 20:05 EST
## Summary

4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology...

## Article Body
4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced a podium presentation at the 44 th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) being held in Montreal, Canada, from July 15 - 18, 2026.

ASRS 2026 Presentation Details:

| Title: | 2-Year Follow Up: PRISM Phase 2b Clinical Trial Evaluating Investigational 4D-150, an Intravitreal Gene Therapy, in a Broad Neovascular AMD Population |
| --- | --- |
| Date/Time: | Saturday, July 18, 2026 (2:58 – 3:01 p.m. ET) |
| Presenter: | Carl Awh, MD, FASRS, Tennessee Retina |

The presentation will also be available on the 4DMT website: https://4dmoleculartherapeutics.com/pipeline/#posters-and-publications

About 4DMT

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™ and the 4DMT logo are trademarks of 4DMT.

All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied. Learn more at www.4DMT.com and follow us on LinkedIn .

Contacts:

Media:

Jenn Gordon dna Communications Media@4DMT.com

Investors:

Julian Pei Head of Investor Relations and Strategic Finance Investor.Relations@4DMT.com
## Recent Company News
- 2026-07-18 19:15 EST — [4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population](https://biopharmsignal.com/news/FDMT/4dmt-announces-positive-2-year-data-from-prism-phase-2b-clinical-trial-in-a-broa-89439f1c) — Source: 4D Molecular Therapeutics, Inc.
- 2026-07-17 20:05 EST — [4DMT Announces New Employment Inducement Grants](https://biopharmsignal.com/news/FDMT/4dmt-announces-new-employment-inducement-grants-681bf23e) — Source: 4D Molecular Therapeutics, Inc.
- 2026-06-30 20:05 EST — [4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists](https://biopharmsignal.com/news/FDMT/4dmt-announces-presentation-at-44th-annual-scientific-meeting-of-the-american-so-2d1eff08) — Source: 4D Molecular Therapeutics, Inc.
- 2026-06-29 12:00 EST — [4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD](https://biopharmsignal.com/news/FDMT/4dmt-completes-enrollment-for-4front-2-global-phase-3-clinical-trial-of-4d-150-i-9bfd89ef) — Source: 4D Molecular Therapeutics, Inc.
- 2026-06-29 12:00 EST — [4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital](https://biopharmsignal.com/news/FDMT/4dmt-secures-strategic-credit-facility-for-up-to-200-million-from-hercules-capit-904f292b) — Source: 4D Molecular Therapeutics, Inc.
## Related News
- 2026-07-28 20:15 EST — BDX — [BD Board Declares Dividend](https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a)
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)